长期双嘧达莫给药减少实验性慢性恰加斯心肌病的心肌灌注缺损
在感染6个月的雌性仓鼠慢性恰加斯心肌病模型中,感染组基线灌注缺损面积大于对照组(P<.05)。双嘧达莫(4 mg/kg,每日两次,腹腔注射)治疗30天后,仅恰加斯+双嘧达莫组灌注缺损从17.3±13.2%降至6.8±7.6%(P=.001);恰加斯+双嘧达莫组和恰加斯+安慰剂组左室射血分数均下降(P<.001)。作者认为长期双嘧达莫减少了静息心肌灌注缺损,支持这些区域对应存活但低灌注心肌。
要点
- 感染6个月仓鼠基线灌注缺损面积感染组大于对照组(P<.05)。
- 双嘧达莫治疗30天后仅恰加斯+双嘧达莫组灌注缺损从17.3±13.2%降至6.8±7.6%(P=.001)。
- 恰加斯+双嘧达莫组和恰加斯+安慰剂组左室射血分数均下降(P<.001)。
核心结论
- 在慢性恰加斯心肌病实验模型中,长期使用双嘧达莫减少了静息心肌灌注缺损,支持这些区域对应存活但低灌注心肌。
研究设计与样本
- 雌性仓鼠在克氏锥虫感染6个月后(基线状态)与对照动物分为四组:感染+双嘧达莫(CH+DIPY)、感染+安慰剂(CH+PLB)、未感染+双嘧达莫(CO+DIPY)、未感染+安慰剂(CO+PLB)。
- 动物接受超声心动图和静息SPECT-甲氧基异丁基异腈-Tc99m心肌灌注显像,随后以双嘧达莫(4 mg/kg,每日两次,腹腔注射)或生理盐水治疗30天,再用同样影像方法复评。
主要发现
- 基线时CH+PLB组和CH+DIPY组灌注缺损面积分别为13.2±13.2%和17.3±13.2%,大于CO+PLB组和CO+DIPY组的3.8±2.2%和3.5±2.7%(P<.05)。
- 治疗后仅CH+DIPY组灌注缺损从17.3±13.2%降至6.8±7.6%(P=.001)。
- CH+DIPY组左室射血分数从65.3±9.0%降至53.6±6.9%,CH+PLB组从69.3±5.0%降至54.4±8.6%(P<.001)。
- 定量组织学显示两个恰加斯组炎症和间质纤维化程度均大于对照组(P<.001),但两个恰加斯组之间无差异(P>.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myocardial perfusion defects (MPD) due to coronary microvascular dysfunction is frequent in chronic Chagas cardiomyopathy (CCC) and may be involved with development of myocardial damage. We investigated whether MPD precedes left ventricular systolic dysfunction and tested the hypothesis that prolonged use of dipyridamole (DIPY) could reduce MPD in an experimental model of CCC in hamsters. METHODS AND RESULTS: We investigated female hamsters 6-months after T. cruzi infection (baseline condition) and control animals, divided into T. cruzi-infected animals treated with DIPY (CH + DIPY) or placebo (CH + PLB); and uninfected animals treated with DIPY (CO + DIPY) or placebo (CO + PLB). The animals were submitted to echocardiogram and rest SPECT-Sestamibi-Tc99m myocardial perfusion scintigraphy. Next, the animals were treated with DIPY (4 mg/kg bid, intraperitoneal) or saline for 30 days, and reevaluated with the same imaging methods. At baseline, the CH + PLB and CH + DIPY groups showed larger areas of perfusion defect (13.2 ± 13.2% and 17.3 ± 13.2%, respectively) compared with CO + PLB and CO + DIPY (3.8 ± 2.2% e 3.5 ± 2.7%, respectively), P < .05. After treatment, we observed: reduction of perfusion defects only in the CH + DIPY group (17.3 ± 13.2% to 6.8 ± 7.6%, P = .001) and reduction of LVEF in CH + DIPY and CH + PLB groups (from 65.3 ± 9.0% to 53.6 ± 6.9% and from 69.3 ± 5.0% to 54.4 ± 8.6%, respectively, P < .001). Quantitative histology revealed greater extents of inflammation and interstitial fibrosis in both Chagas groups, compared with control group (P < .001), but no difference between Chagas groups (P > .05). CONCLUSIONS: The prolonged use of DIPY in this experimental model of CCC has reduced the rest myocardial perfusion defects, supporting the notion that those areas correspond to viable hypoperfused myocardium.
引用
- Tanaka DM, de Oliveira LFL, Marin-Neto JA, et al. Prolonged dipyridamole administration reduces myocardial perfusion defects in experimental chronic Chagas cardiomyopathy. J Nucl Cardiol. 2018. PMID: 29392628. doi:10.1007/s12350-018-1198-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。